MedTrace Logo

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00002817 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-01-10

No results posted yet for this study

Summary

RATIONALE: Vaccines may make the body build an immune response to kill melanoma cells.

PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients with metastatic melanoma.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

sargramostim

BIOLOGICAL

vaccinia-GM-CSF vaccine

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    lead OTHER

Principal Investigators

  • Michael J. Mastrangelo, MD · Sidney Kimmel Cancer Center at Thomas Jefferson University

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002817 on ClinicalTrials.gov